{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:36:03Z","timestamp":1792449363951,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1124\/jpet.119.261511","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T01:55:11Z","timestamp":1574301311000},"page":"205-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention"],"prefix":"10.1016","volume":"372","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-5397","authenticated-orcid":false,"given":"David R.","family":"Maguire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Gerak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerta","family":"Cami-Kobeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-6322","authenticated-orcid":false,"given":"Stephen M.","family":"Husbands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P.","family":"France","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.261511_bib1","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1111\/bph.14060","article-title":"Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed \u03ba\/\u03bc receptor antagonist properties, in mice","volume":"175","author":"Almatroudi","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.261511_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/17460441.2014.964203","article-title":"Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies","volume":"9","author":"Bailey","year":"2014","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/jpet.119.261511_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-008-1293-6","article-title":"Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys","volume":"201","author":"Becker","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.261511_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","article-title":"The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors","volume":"1314","author":"Bruchas","year":"2010","journal-title":"Brain Res"},{"key":"10.1124\/jpet.119.261511_bib5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41386-018-0046-4","article-title":"Kappa-opioid antagonists as stress resilience medications for the treatment of alcohol use disorders","volume":"43","author":"Chavkin","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.119.261511_bib6","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0022-3565(25)39443-7","article-title":"Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced responding in rats","volume":"267","author":"Comer","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.261511_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/adb.12020","article-title":"A non-rewarding, non-aversive buprenorphine\/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm","volume":"19","author":"Cordery","year":"2014","journal-title":"Addict Biol"},{"key":"10.1124\/jpet.119.261511_bib8","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1021\/acs.jmedchem.5b00130","article-title":"C7\u03b2-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin\/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors","volume":"58","author":"Cueva","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.261511_bib9","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.119.261511_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2125.2012.04474.x","article-title":"Future pharmacological treatments for substance use disorders","volume":"77","author":"Forray","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.119.261511_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/jpet.115.231381","article-title":"Combined treatment with morphine and \u03949-tetrahydrocannabinol in rhesus monkeys: antinociceptive tolerance and withdrawal","volume":"357","author":"Gerak","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.261511_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-009-1471-1","article-title":"Self administration of heroin and cocaine in morphine-dependent and morphine-withdrawn rhesus monkeys","volume":"204","author":"Gerak","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.261511_bib13","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s00213-015-4023-x","article-title":"Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys","volume":"232","author":"Gerak","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1124\/jpet.119.261511_bib31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.116.236307","article-title":"Effects of Lorcaserin on Cocaine and Methamphetamine Self-Administration and Reinstatement of Responding Previously Maintained by Cocaine in Rhesus Monkeys","volume":"359","author":"Gerak","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1124\/jpet.119.261511_bib32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1037\/pha0000234","article-title":"Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys","volume":"27","author":"Gerak","year":"2019","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/jpet.119.261511_bib14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0269881106060835","article-title":"Naltrexone and buprenorphine combination in the treatment of opioid dependence","volume":"20","author":"Gerra","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.119.261511_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s002130050688","article-title":"Naltrexone treatment of comorbid alcohol and cocaine use disorders","volume":"139","author":"Hersh","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.261511_bib16","series-title":"Research & Development of Opioid-Related Analgesics","first-page":"127","article-title":"Buprenorphine and related orvinols","author":"Husbands","year":"2013"},{"key":"10.1124\/jpet.119.261511_bib17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.119.261511_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1124\/jpet.118.252353","article-title":"Long-lasting effects of methocinnamox on opioid self-administration in rhesus monkeys","volume":"368","author":"Maguire","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.261511_bib21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.clpt.6100503","article-title":"Potential of buprenorphine\/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders","volume":"83","author":"McCann","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.261511_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1465-3362.2012.00470.x","article-title":"Substance use initiation: the role of simultaneous polysubstance use","volume":"32","author":"Olthuis","year":"2013","journal-title":"Drug Alcohol Rev"},{"key":"10.1124\/jpet.119.261511_bib23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/10826080802347545","article-title":"Settings and functions related to simultaneous use of alcohol with marijuana or cocaine among clients in treatment for substance abuse","volume":"44","author":"Pakula","year":"2009","journal-title":"Subst Use Misuse"},{"key":"10.1124\/jpet.119.261511_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.9740\/mhc.2018.07.175","article-title":"Kappa opioid receptor antagonism: are opioids the answer for treatment resistant depression?","volume":"8","author":"Peckham","year":"2018","journal-title":"Ment Health Clin"},{"key":"10.1124\/jpet.119.261511_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2016.10.050","article-title":"A role for the mu opioid receptor in the antidepressant effects of buprenorphine","volume":"319","author":"Robinson","year":"2017","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.119.261511_bib26","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","volume":"12","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/jpet.119.261511_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0740-5472(99)00074-4","article-title":"An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence","volume":"18","author":"Rothman","year":"2000","journal-title":"J Subst Abuse Treat"},{"key":"10.1124\/jpet.119.261511_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00213-011-2263-y","article-title":"Translational and reverse translational research on the role of stress in drug craving and relapse","volume":"218","author":"Sinha","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.261511_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1734-1140(11)70484-4","article-title":"Transdermal delivery of a buprenorphine\/naltrexone combination for the treatment of polydrug abuse","volume":"63","author":"Taverner","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1124\/jpet.119.261511_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00213-013-3195-5","article-title":"Role of kappa-opioid receptors in stress and anxiety-related behavior","volume":"229","author":"Van\u2019t Veer","year":"2013","journal-title":"Psychopharmacology (Berl)"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524269159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524269159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.261511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:59:02Z","timestamp":1739973542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524269159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0022356524269159"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.261511","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.261511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}